Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data

This study aimed to develop a population pharmacokinetic (PK) model of ambrisentan in pediatric patients (8 to

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2023-05, Vol.63 (5), p.593-603
Main Authors: Okour, Malek, Thapar, Mita M., Farrell, Colm, Lukas, Mary Ann, Beghetti, Maurice, Beerahee, Misba
Format: Article
Language:English
Subjects:
6‐minute walking distance
Adult
Adverse events
ambrisentan
Antihypertensive Agents
Body weight
Child
Dosage
exposure–response
Familial Primary Pulmonary Hypertension
Humans
Hypertension
Pediatrics
pharmacokinetic model
Pharmacokinetics
Phenylpropionates - adverse effects
Phenylpropionates - pharmacokinetics
pulmonary arterial hypertension
Pulmonary Arterial Hypertension - chemically induced
Pulmonary Arterial Hypertension - drug therapy
Pulmonary hypertension
Pyridazines - adverse effects
Pyridazines - pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to develop a population pharmacokinetic (PK) model of ambrisentan in pediatric patients (8 to
ISSN:0091-2700
1552-4604
DOI:10.1002/jcph.2199